Fig. 1: COS treatment ameliorates depressive-like behavior of male mice. | Acta Pharmacologica Sinica

Fig. 1: COS treatment ameliorates depressive-like behavior of male mice.

From: Costunolide normalizes neuroinflammation and improves neurogenesis deficits in a mouse model of depression through inhibiting microglial Akt/mTOR/NF-κB pathway

Fig. 1

a The experimental timeline. b–e Behavioral tests showed that intra-DG injection of COS (5 μM, 1 μL per side) ameliorated depressive-like behavior in CRS-exposed mice, including increased sucrose preference in SPT (b), decreased immobility time in TST (c) and FST (d), increased grooming time in ST (e) (n = 7 mice per group). f Open-field test showed that COS did not affect locomotor activity of mice (n = 7 mice per group). g The experimental timeline. h–k Behavioral tests showed that COS (20 mg/kg, i.p.) produced antidepressant action in CRS-exposed mice, including increased sucrose preference in SPT (h), decreased immobility time in TST (i) and FST (j), increased grooming time in ST (k) (n = 7 mice per group). l Open-field test showed that COS did not affect locomotor activity of mice (n = 7 mice per group). Data are presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 by two-way ANOVA (b–f, h–l) followed by Sidak’s post hoc test. The statistical details can be found in Supplementary Table S1.

Back to article page